Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
1 other identifier
expanded_access
N/A
1 country
16
Brief Summary
The objective of the study is to provide access to TAS-120 to patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
16 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 7, 2020
CompletedFirst Posted
Study publicly available on registry
August 11, 2020
CompletedMarch 10, 2026
March 1, 2026
August 7, 2020
March 9, 2026
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Provide written informed consent.
- \>18 years of age.
- Histologically confirmed, locally advanced, or metastatic, or recurrent unresectable CCA harboring FGFR2 gene rearrangements based on testing performed by a qualified (CLIA-certified) laboratory.
- Patient has failed standard therapy or standard therapy is not tolerated.
- Has measurable or non-measurable lesion(s).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Adequate organ function.
You may not qualify if:
- History and/or current evidence of non-tumor related alteration of calcium-phosphorus homeostasis.
- History and/or current evidence of clinically significant ectopic mineralization/calcification.
- History and/or current evidence of clinically significant retinal disorder confirmed by retinal examination.
- A serious illness or medical condition(s)
- Pregnant or breast-feeding female
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (16)
Banner MD Anderson
Gilbert, Arizona, 85234, United States
University of California, San Francisco (UCSF)
San Francisco, California, 94143, United States
UCLA Division of Hematology-Oncology
Santa Monica, California, 90404, United States
Mount Sinai Center of Florida
Miami Beach, Florida, 33140, United States
Advent Health Orlando
Orlando, Florida, 32804, United States
University of Chicago
Chicago, Illinois, 60637, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
University of Kansas Cancer Center
Lee's Summit, Missouri, 64064, United States
Duke University Medical Center
Durham, North Carolina, 27710, United States
Providence Portland Medical Center
Portland, Oregon, 97213, United States
MD Anderson
Houston, Texas, 77030, United States
Utah Cancer Specialists
Salt Lake City, Utah, 84106, United States
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
Aurora Cancer care
Grafton, Wisconsin, 53024, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 7, 2020
First Posted
August 11, 2020
Last Updated
March 10, 2026
Record last verified: 2026-03